Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 37

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 4I
Chunk 37
---
 In June 2019, Genmab entered into an exclusive worldwide license and option agreement with J&J to develop and commercialize HexaBody-CD38. In March 2021 we initiated a Phase I/II clinical trial of HexaBody-CD38 for the 

45

treatment of hematologic malignancies. Preliminary dose-escalation results from the trial were presented at the ASH Annual Meeting in December 2022. This was followed by preliminary results from a dose-expansion cohort, which was presented at the ASH Annual Meeting in December 2023. This study includes an arm comparing HexaBody-CD38 to daratumumab in CD38 monoclonal antibody-naïve R/R MM patients.
In December 2024, per the terms of the agreement between Genmab and J&J, Genmab submitted a data package to J&J, comparing HexaBody-CD38 to daratumumab in CD38 monoclonal antibody-naïve R/R MM patients. This data will be used to inform J&J’s decision on whether to exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38.
DuoBody-EpCAMx4-1BB (GEN1059/BNT314)
DuoBody-EpCAMx4-1BB, jointly owned by Genmab and BioNTech and created using Genmab’s DuoBody technology platform, is a bispecific antibody aimed at boosting antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity. DuoBody-EpCAMx4-1BB is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for DuoBody-EpCAMx4-1BB on a 50:50 basis. A Phase I/II clinical trial of DuoBody-EpCAMx4-1BB in solid tumors is recruiting. 
HexaBody-OX40 (GEN1055/BNT315)
HexaBody-OX40, jointly owned by Genmab and BioNTech and created using Genmab’s HexaBody technology platform, is an immune-modulating OX40 agonist antibody designed to promote immunity by enhancing T-cell responses through FcγR-independent OX40 clustering on T cells. HexaBody-OX40is being co-developed by Genmab and BioNTech under an agreement in which the